Federal award (PURCHASE ORDER, fiscal year 2021)
Recipient: CATALYST PHARMACEUTICALS, INC
Awarding agency: Department of Defense / Defense Threat Reduction Agency
Funding agency: Department of Defense / Defense Threat Reduction Agency
Period of performance: 2021-03-22 to 2022-01-31
Current total value of award: $86650
Description: INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR THE PURPOSE OF A DRUG REPURPOSING EFFORT OF AN APPROVED DRUG, 3,4- DIAMINOPYRIDINE PHOSPHATE